Exhibit 99.1

                                           COMPANY CONTACT:

                                           Steve Loomis, Chief Financial Officer
                                           CardioDynamics
                                           800-778-4825, Ext. 1015
                                           sloomis@cdic.com


            CardioDynamics Announces Over $2M of International Sales
                        for Two Large Hospital Customers

             International Business Experiencing Accelerated Growth

SAN DIEGO, CA--January 15, 2008--CardioDynamics (Nasdaq: CDIC), the innovator
and leader of Impedance Cardiography (ICG) technology, today announced shipments
of over $2 million of ICG NICCOMO(TM) monitoring systems to two large
international hospital customers. Approximately $1.8 million of NICCOMO
monitors, the Company's largest sale ever of these systems, were ordered, paid
for, and shipped during November 2007 through January 2008 to an undisclosed (at
the customer's request) eastern European hospital purchaser. Additionally, the
Instituto de Salud del Estado de Mexico (ISEM), the hospital network of the
state of Mexico within the country of Mexico, purchased over $200,000 of NICCOMO
monitors early in January 2008.

The ICG monitors provided to ISEM will be installed in the intensive care units
of 10 hospitals throughout Mexico and were purchased to provide advanced
healthcare service in the intensive care units within ISEM. This sale was a
follow-on order to a previous sale of BioZ ICG monitors to the same customer in
2006.




Michael K. Perry, Chief Executive Officer of CardioDynamics, stated, "We are
very pleased with the acceleration in growth that we have seen recently from our
international sales regions. During the fourth quarter 2007, international
revenue increased over 50% from fourth quarter 2006, and with the sale to
Mexico, coupled with the second half shipment of the large European sale, we are
off to a very good start in fiscal 2008. Additionally, over the past several
quarters we have seen steady improvement in sales of BioZ(R) ICG modules to
Mindray, which is the largest patient monitoring company in China and whose
sales have grown consistently at over 40% per annum over the last several
years."

Perry added, "Both of these large customers purchased ICG devices designed and
manufactured by our Medis division which we acquired in June 2004. This German
team has been an excellent addition to CardioDynamics delivering consistent,
profitable growth from day one of the acquisition."

The Company's market development strategy for its proprietary ICG technology is
designed to optimize success in both the physician office and hospital markets.
To date, the United States strategy has been principally focused in the
physician office market, which, at this stage in market acceptance, is optimally
served by a direct sales force. Internationally, the Company's primary market
has been in the hospital, where hospital specialty distributors and original
equipment manufacturer (OEM) integration partnerships are integral to success.
Last year, the Company announced its Phoenix Initiative which was a series of
strategies focused on new revenue growth opportunities, including the expansion
of the international ICG market.




Shenzhen Mindray Bio-Medical Electronics co., Ltd., located in Shenzhen, China
is engaged in the development, manufacturing, marketing and selling of
electro-medical equipment in the patient monitoring, laboratory instrument and
medical ultrasound fields. With annual sales growing at 40% in recent years,
Mindray has positioned itself as one of the largest medical equipment providers
in China since its establishment in 1991. Additional information can be found on
the company's website at http://www.mindray.com.

About CardioDynamics:

CardioDynamics (Nasdaq: CDIC), the ICG Company, is the innovator and leader of
breakthrough medical technology called Impedance Cardiography (ICG). The Company
develops, manufactures and markets noninvasive diagnostic and monitoring
technologies and electrodes. The Company's ICG Systems are being used by
physicians around the world to help battle the number one killer of men and
women--cardiovascular disease. Partners include GE Healthcare and Philips
Medical Systems. For additional information, please refer to the company's Web
site at www.cdic.com.

Forward-Looking (Safe Harbor) Statement:

Except for the historical and factual information contained herein, this press
release contains forward-looking statements, such as potential growth rates,
success of strategic partner relationships including potential increased
hospital market penetration, the accuracy of which is necessarily subject to
uncertainties and risks including the Company's primary dependence on the BioZ
product line, and various uncertainties characteristic of early growth
companies, as well as other risks detailed in the Company's filings with the
SEC, including its 2006 Form 10-K. The Company does not undertake to update the
disclosures contained in this press release.